[Digital Ulcers in Systemic Sclerosis : A Retrospective Heath Service Study Analysing Treatment with Bosentan and Other Vasoactive Therapies]

Overview

Journal Z Rheumatol

Publisher Springer

Specialty Rheumatology

Date 2016 Aug 19

PMID 27535277

Authors

G Riemekasten

S Beissert

J H W Distler

A Kreuter

U Muller-Ladner

Affiliations

Soon will be listed here.

Abstract

Background: Digital ulcers (DU) affect up to 60 % of patients with systemic sclerosis (SSc) and have a considerable impact on quality of life and morbidity. It is unclear to what extent authorised medicines are used, and if therapy guidelines are implemented in everyday practice.

Method: This retrospective health care study examined current standards of treatment for therapy and prevention of SSc-associated DU in an online survey with 83 physicians. Additionally, data from 161 case studies of SSc patients with DU were analysed, and the effect of DU treatment on the course of the disease determined.

Results: For treatment and prevention of active DU, physicians predominantly indicated topical therapies, calcium channel blockers, iloprost and endothelin receptor antagonists. According to the case studies, 90 % of episodes with acute DU were treated with bosentan and iloprost in mono- or combination therapy. Preventive treatment was only administered during 50 % of episodes without DU, even after three or more phases with active DU. For the prevention of new DU, bosentan was used in mono- or combination therapy in 57 % of episodes without DU. Bosentan therapy during prevention shortened the following acute phase by 32 %. Additionally, continuous treatment with bosentan in acute and prevention phases reduced the duration of the following acute phase and increased the time to onset of new DU by 16 %. Moreover, bosentan stabilised the number of new DU.

Conclusion: In summary, these data confirm the efficacy of bosentan in preventing new DU when used in DU-free episodes and possibly also in phases of acute DU. Therapy recommendations for the treatment of DU are currently not fully implemented. In the future, even more attention should be paid to DU therapy.

References

Kowal-Bielecka O, Landewe R, Avouac J, Chwiesko S, Miniati I, Czirjak L . EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis. 2009; 68(5):620-8. DOI: 10.1136/ard.2008.096677. View

Brand M, Hollaender R, Rosenberg D, Scott M, Hunsche E, Tyndall A . An observational cohort study of patients with newly diagnosed digital ulcer disease secondary to systemic sclerosis registered in the EUSTAR database. Clin Exp Rheumatol. 2015; 33(4 Suppl 91):S47-54. View

Riemekasten G, Hoffmann U, Sunderkotter C, Weiss N, Kuhn A . [Management of digital ulcers in patients with systemic sclerosis]. Dtsch Med Wochenschr. 2011; 137(1-2):34-40. DOI: 10.1055/s-0031-1298798. View

Sunderkotter C, Herrgott I, Bruckner C, Moinzadeh P, Pfeiffer C, Gerss J . Comparison of patients with and without digital ulcers in systemic sclerosis: detection of possible risk factors. Br J Dermatol. 2009; 160(4):835-43. DOI: 10.1111/j.1365-2133.2008.09004.x. View

Kowal-Bielecka O, Fransen J, Avouac J, Becker M, Kulak A, Allanore Y . Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2016; 76(8):1327-1339. DOI: 10.1136/annrheumdis-2016-209909. View

Mouthon L, Mestre-Stanislas C, Berezne A, Rannou F, Guilpain P, Revel M . Impact of digital ulcers on disability and health-related quality of life in systemic sclerosis. Ann Rheum Dis. 2009; 69(1):214-7. DOI: 10.1136/ard.2008.094193. View

Korn J, Mayes M, Cerinic M, Rainisio M, Pope J, Hachulla E . Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum. 2004; 50(12):3985-93. DOI: 10.1002/art.20676. View

Merkel P, Herlyn K, Martin R, Anderson J, Mayes M, Bell P . Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon. Arthritis Rheum. 2002; 46(9):2410-20. DOI: 10.1002/art.10486. View

Matucci-Cerinic M, Denton C, Furst D, Mayes M, Hsu V, Carpentier P . Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2010; 70(1):32-8. PMC: 3002766. DOI: 10.1136/ard.2010.130658. View

10.

Hachulla E, Hatron P, Carpentier P, Agard C, Chatelus E, Jego P . Efficacy of sildenafil on ischaemic digital ulcer healing in systemic sclerosis: the placebo-controlled SEDUCE study. Ann Rheum Dis. 2015; 75(6):1009-15. PMC: 4893100. DOI: 10.1136/annrheumdis-2014-207001. View

11.

Hachulla E, Clerson P, Launay D, Lambert M, Morell-Dubois S, Queyrel V . Natural history of ischemic digital ulcers in systemic sclerosis: single-center retrospective longitudinal study. J Rheumatol. 2007; 34(12):2423-30. View

12.

Steen V, Denton C, Pope J, Matucci-Cerinic M . Digital ulcers: overt vascular disease in systemic sclerosis. Rheumatology (Oxford). 2009; 48 Suppl 3:iii19-24. DOI: 10.1093/rheumatology/kep105. View

13.

Tingey T, Shu J, Smuczek J, Pope J . Meta-analysis of healing and prevention of digital ulcers in systemic sclerosis. Arthritis Care Res (Hoboken). 2013; 65(9):1460-71. DOI: 10.1002/acr.22018. View

14.

Moinzadeh P, Riemekasten G, Siegert E, Fierlbeck G, Henes J, Blank N . Vasoactive Therapy in Systemic Sclerosis: Real-life Therapeutic Practice in More Than 3000 Patients. J Rheumatol. 2015; 43(1):66-74. DOI: 10.3899/jrheum.150382. View

15.

Khanna D, Denton C, Merkel P, Krieg T, Le Brun F, Marr A . Effect of Macitentan on the Development of New Ischemic Digital Ulcers in Patients With Systemic Sclerosis: DUAL-1 and DUAL-2 Randomized Clinical Trials. JAMA. 2016; 315(18):1975-88. DOI: 10.1001/jama.2016.5258. View

16.

Mihai C, Landewe R, van der Heijde D, Walker U, Constantin P, Gherghe A . Digital ulcers predict a worse disease course in patients with systemic sclerosis. Ann Rheum Dis. 2015; 75(4):681-6. DOI: 10.1136/annrheumdis-2014-205897. View